INNO-GENE SA ZY -10 (WQ3) - Total Liabilities
Based on the latest financial reports, INNO-GENE SA ZY -10 (WQ3) has total liabilities worth €7.45 Million EUR (≈ $8.71 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of INNO-GENE SA ZY -10 to evaluate the company's liquid asset resilience ratio.
INNO-GENE SA ZY -10 - Total Liabilities Trend (2021–2024)
This chart illustrates how INNO-GENE SA ZY -10's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see INNO-GENE SA ZY -10 balance sheet assets.
INNO-GENE SA ZY -10 Competitors by Total Liabilities
The table below lists competitors of INNO-GENE SA ZY -10 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
IntegraFin Holdings plc
LSE:IHP
|
UK | GBX35.55 Billion |
|
COSMOS HEALTH NEW DL-01
F:V67A
|
Germany | €47.05 Million |
|
Cocrystal Pharma Inc
NASDAQ:COCP
|
USA | $3.31 Million |
|
BIFIDO Co. Ltd
KQ:238200
|
Korea | ₩12.57 Billion |
|
Applied Therapeutics Inc
NASDAQ:APLT
|
USA | $34.94 Million |
|
Dome Gold Mines Ltd
AU:DME
|
Australia | AU$1.39 Million |
|
Paterson Resources Ltd
AU:PSL
|
Australia | AU$105.61K |
|
iRobot Corporation
NASDAQ:IRBT
|
USA | $508.46 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down INNO-GENE SA ZY -10's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See WQ3 equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how INNO-GENE SA ZY -10's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for INNO-GENE SA ZY -10 (2021–2024)
The table below shows the annual total liabilities of INNO-GENE SA ZY -10 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €6.50 Million ≈ $7.60 Million |
+106.02% |
| 2023-12-31 | €3.16 Million ≈ $3.69 Million |
+42.28% |
| 2022-12-31 | €2.22 Million ≈ $2.59 Million |
-60.38% |
| 2021-12-31 | €5.60 Million ≈ $6.55 Million |
-- |
About INNO-GENE SA ZY -10
HyEnergy S.A. provides genetic diagnostic solutions in Poland. The company also develops and implements diagnostic algorithm for prevention and personalization of treatment of solid tumors. In addition, it provides DNA analysis and genetic diseases diagnostic service based on NGS technology. HyEnergy S.A. was formerly known as Inno-Gene S.A. and changed its name to HyEnergy S.A. in October 2024. … Read more